{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:03:46Z","timestamp":1770887026693,"version":"3.50.1"},"reference-count":36,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13061","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:37:28Z","timestamp":1768570648000},"source":"Crossref","is-referenced-by-count":0,"title":["No increased risk of hepatic enzyme abnormalities with non\u2011peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta\u2011analysis of randomized controlled trials"],"prefix":"10.3892","volume":"31","author":[{"given":"Nan","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Hematology, The Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhou","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyue","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu 223800, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"key20260212100610_b1-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260212100610_b2-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"key20260212100610_b3-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2022.11.022","article-title":"Current approaches for the diagnosis and management of immune thrombocytopenia","volume":"108","author":"Gafter-Gvili","year":"2023","journal-title":"Eur J Intern Med"},{"key":"key20260212100610_b4-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"key20260212100610_b5-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","article-title":"Mechanisms and therapeutic prospects of thrombopoietin receptor agonists","volume":"56","author":"Bussel","year":"2019","journal-title":"Semin Hematol"},{"key":"key20260212100610_b6-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-023-05114-8","article-title":"Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: A systematic review and Central European expert consensus","volume":"102","author":"Pulani\u0107","year":"2023","journal-title":"Ann Hematol"},{"key":"key20260212100610_b7-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2174\/1871530320666200531142244","article-title":"Thrombopoietin receptor agonists in children with immune thrombocytopenia: A new therapeutic era","volume":"21","author":"Lassandro","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"key20260212100610_b8-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1055\/a-2247-4209","article-title":"Update on the use of thrombopoietin-receptor agonists in pediatrics","volume":"44","author":"Gebetsberger","year":"2024","journal-title":"Hamostaseologie"},{"issue":"2253069","key":"key20260212100610_b9-ETM-31-3-13061","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2253069","article-title":"Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort","volume":"28","author":"Lucchesi","year":"2023","journal-title":"Hematology"},{"issue":"n71","key":"key20260212100610_b10-ETM-31-3-13061","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20260212100610_b11-ETM-31-3-13061","author":"Higgins"},{"key":"key20260212100610_b12-ETM-31-3-13061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American society of hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"issue":"l4898","key":"key20260212100610_b13-ETM-31-3-13061","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key20260212100610_b14-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"key20260212100610_b15-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"key20260212100610_b16-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"key20260212100610_b17-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key20260212100610_b18-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): A randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"key20260212100610_b19-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br J Haematol"},{"key":"key20260212100610_b20-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3760\/cma.j.issn.0253-2727.2018.01.007","article-title":"The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"39","author":"Huang","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"key20260212100610_b21-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3026(20)30227-1","article-title":"Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: A non-inferiority, multicentre, randomised trial","volume":"7","author":"Arnold","year":"2020","journal-title":"Lancet Haematol"},{"key":"key20260212100610_b22-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.17808","article-title":"A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients","volume":"195","author":"Mei","year":"2021","journal-title":"Br J Haematol"},{"key":"key20260212100610_b23-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"key":"key20260212100610_b24-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"37","key":"key20260212100610_b25-ETM-31-3-13061","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: A novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"key20260212100610_b26-ETM-31-3-13061","first-page":"503","article-title":"Effect analysis of recombinant human thrombopoietin and herombopag on immune function in patients with primary immune thrombocytopenia","volume":"47","author":"Sun","year":"2024","journal-title":"Int J Blood Transfus Hematol"},{"issue":"46","key":"key20260212100610_b27-ETM-31-3-13061","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00873-8","article-title":"Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: A pharmacovigilance study based on the FDA adverse event reporting system","volume":"26","author":"Wang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"key20260212100610_b28-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1124\/dmd.111.040170","article-title":"Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects","volume":"39","author":"Deng","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"key20260212100610_b29-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/cpdd.349","article-title":"Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects","volume":"7","author":"Nomoto","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key20260212100610_b30-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals","volume":"121","author":"Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20260212100610_b31-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/bcp.15664","article-title":"A phase I, single-sequence, open-label study to evaluate the drug-drug interaction between hetrombopag and cyclosporine in healthy Chinese subjects","volume":"89","author":"Li","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"key20260212100610_b32-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: Final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"key20260212100610_b33-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"key20260212100610_b34-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.21037\/apm-21-1067","article-title":"Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"key20260212100610_b35-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/asheducation-2018.1.405","article-title":"Pediatric ITP: Is it different from adult ITP?","volume":"2018","author":"Despotovic","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20260212100610_b36-ETM-31-3-13061","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:06:21Z","timestamp":1770883581000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13061","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"66"}}